Lyophilised Oral Faecal Microbiota Transplantation in Ulcerative Colitis - a Randomised Placebo-Controlled Trial

溃疡性结肠炎 粪便细菌疗法 安慰剂 医学 内科学 随机对照试验 移植 结肠炎 粪便 胃肠病学 生物 微生物学 替代医学 病理 疾病 抗生素 艰难梭菌
作者
Craig Haifer,Sudarshan Paramsothy,Nadeem Omar Kaakoush,Aiasha Saikal,Simon Ghaly,Laurence Don Wai Luu,Thomas Julius Borody,Rupert Wing Loong Leong
出处
期刊:Social Science Research Network [RELX Group (Netherlands)]
标识
DOI:10.2139/ssrn.3931753
摘要

Background: Colonoscopic infusion and enemas of faecal microbiota transplantation (FMT) induce remission in ulcerative colitis (UC) but whether oral FMT achieves induction and maintenance of remission in UC is unknown.Methods: A double-blind, randomised placebo-controlled trial was conducted. Following 2-weeks of amoxicillin, metronidazole and doxycycline, patients with active UC were randomised 1:1 to FMT or placebo capsules for 8-weeks. The primary outcome was steroid-free clinical remission with endoscopic remission or response. At week-8, FMT-responders were re-randomised 1:1 to continue or withdraw FMT for a further 48-weeks. Modified intention-to-treat analysis was performed and included all patients who received at least one study dose. The gastrointestinal microbiota was profiled using 16S rRNA and ITS region amplicon sequencing. This report presents the final analysis.Findings: From May 2019 to March 2020, 35 subjects were randomised (15 FMT/ 20 placebo). Recruitment was terminated early due to the SARS-COV-2 pandemic. The primary outcome was achieved in 8/15(53%) with FMT versus 3/20(15%) with placebo (difference:38·3% [95%CI: 8·6–68·0]; P =0·027; OR:5·0[95%CI: 1·8–14·1]). Ten FMT-responders entered the maintenance phase. By 56-weeks, 6/6 (100%) subjects randomised to withdraw FMT relapsed (median time to treatment escalation 24-weeks); whereas 4/4(100%) subjects on maintenance-FMT had endoscopic and histologic mucosal healing. Adverse events occurred in 10/15(67%) FMT and 18/20(85%) placebo subjects and were generally mild and self-limiting. Serious adverse events included worsening UC (2 FMT, 1 placebo) and PR bleeding (1 placebo). Antibiotics reduced pathobionts and FMT increased species richness relative to placebo (P<0·0001). Therapeutic effectiveness was associated with high donor microbial alpha-diversity and Bacteroides species, and increases in Bacteroides ovatus-like taxa in recipients.Interpretation Antibiotics followed by orally-administered FMT induces remission in subjects with active UC with corresponding microbial changes. Maintenance FMT in responders was safe, well tolerated and appeared to sustain the response achieved during induction therapy. Trial Registration: The study was registered with the Australian New Zealand Clinical Trial Registry ACTRN12619000611123.Funding: The study was supported by: St Vincent’s Clinic Foundation (2019), Gastroenterological Society of Australia (2020) and Gutsy Group (202-2021). CH is supported by a Research Entry Scholarship through the Royal Australasian College of Physicians; SP is supported by an NHMRC Investigator Grant, NOK is supported by a Scientia Fellowship from UNSW.Declaration of Interest: CH reports speaker fees and educational support from Janssen, Pfizer, Takeda, Ferring, Sandoz and Abbvie. SP has served as a consultant for Finch Therapeutics and has received speaker fees from Ferring, Janssen and Takeda. SG reports Speaker fees, educational grants or travel sponsorship from Janssen Cilag, AbbVie, Takeda, Ferring, Shire, Pfizer. Advisory board fees Pfizer and AbbVie. TJB has a pecuniary interest in the Centre for Digestive Diseases, is a medical advisor to Finch therapeutics and holds patents in FMT treatment. RWL reports personal fees from AbbVie, personal fees from Aspen, personal fees from Ferring, grants and personal fees from Hospira/ Pfizer, grants and personal fees from Janssen, grants and personal fees from Takeda, grants from Shire, grants from NHMRC, personal fees from Celgene, personal fees from Dr Falk Pharma, personal fees from Novartis, personal fees from MSD, grants from Gutsy Group, personal fees from Chiesi, personal fees from BMS, personal fees from Glutagen, outside the submitted work. All other authors have no conflicts of interest to declare.Ethical Approval: This investigator-initiated study was approved by the St Vincent’s Hospital Sydney Human Research Ethics Committee (HREC/18/SVH/219) with The University of Sydney serving as study sponsor. All patients provided written informed consent.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
齐次的雨发布了新的文献求助10
刚刚
无花果的应助被Iace6pack采纳,获得10
1秒前
CarryLJR发布了新的文献求助30
1秒前
1秒前
香蕉三娘完成签到,获得积分10
1秒前
wanci的应助被一笑半步巅采纳,获得10
1秒前
CipherSage的应助被ZM采纳,获得10
2秒前
2秒前
思源的应助被Cr采纳,获得10
2秒前
蜉蝣完成签到,获得积分10
2秒前
新楚发布了新的文献求助10
2秒前
大个的应助被火星上的无声采纳,获得10
2秒前
知晏发布了新的文献求助10
3秒前
LLMs完成签到,获得积分10
3秒前
li完成签到,获得积分10
4秒前
Galaxy完成签到,获得积分10
4秒前
核桃发布了新的文献求助10
4秒前
amity发布了新的文献求助10
4秒前
4秒前
爱吃橘子发布了新的文献求助10
4秒前
huang完成签到,获得积分10
4秒前
5秒前
Maestro_S的应助被sunny采纳,获得10
5秒前
懒羊羊发布了新的文献求助10
5秒前
5秒前
天天向上的应助被Chen采纳,获得10
6秒前
7秒前
Lee发布了新的文献求助10
7秒前
32kekediffers完成签到,获得积分10
7秒前
微笑萝完成签到,获得积分10
7秒前
7秒前
不知道起个什么名字完成签到 ,获得积分10
8秒前
Lucas的应助被漫离采纳,获得10
8秒前
111完成签到 ,获得积分10
8秒前
9秒前
欣然快乐完成签到,获得积分20
9秒前
小二郎的应助被LILILILI采纳,获得30
9秒前
9秒前
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175853
求助须知:如何正确求助?哪些是违规求助? 9567457
关于积分的说明 21792632
捐赠科研通 7770447
什么是DOI,文献DOI怎么找? 3431918
关于科研通互助平台的介绍 2556276
邀请新用户注册赠送积分活动 2477418